Literature DB >> 20883735

Baculovirus as an avian influenza vaccine vector: differential immune responses elicited by different vector forms.

Chi-Yuan Chen1, Hung-Jen Liu, Ching-Ping Tsai, Cheng-Yu Chung, Yung-Shen Shih, Poa-Chun Chang, Yung-Tsung Chiu, Yu-Chen Hu.   

Abstract

Baculovirus is an enveloped virus that infects insects in nature and has emerged as a novel vaccine vector. We previously constructed a recombinant baculovirus displaying the hemagglutinin protein (HA) of avian influenza virus (AIV) on the viral envelope (Bac-HA64), and demonstrated the induction of humoral responses in immunized mice. To improve the vector design and explore how the vector forms influence the vaccine efficacy, we constructed two more baculoviruses Bac-CHA and Bac-CHA/HA64. Bac-CHA expressed HA after transducing the host cells while Bac-CHA/HA64 not only expressed HA but also displayed HA on the envelope. After administration into BALB/c mice, all three vectors elicited HA-specific humoral (IgG1, IgG2a and hemagglutination inhibition titers), mucosal (IgA titers) and cellular (interferon (IFN)-γ and IL-4 producing T cells and IFN-γ(+)/CD8(+) T cells) immune responses. Intriguingly, the magnitudes and types of responses hinged on the vaccine form and administration route. Via intranasal (i.n.) and subcutaneous (s.c.) inoculation, the HA-displaying vectors Bac-HA64 and Bac-CHA/HA64 triggered stronger humoral and mucosal responses than Bac-CHA, but upon intramuscular (i.m.) injection the HA-expressing vectors (Bac-CHA and Bac-CHA/2HA64) elicited more robust humoral and cellular responses than Bac-HA64. Via either administration route, the dual form vaccine Bac-CHA/HA64 gave rise to superior or at least comparable HA-specific immune responses than the other two vaccine forms, implicating the potential of Bac-CHA/HA64 as a vaccine candidate against AIV infection.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20883735     DOI: 10.1016/j.vaccine.2010.09.048

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Adaptive immune responses elicited by baculovirus and impacts on subsequent transgene expression in vivo.

Authors:  Wen-Yi Luo; Shih-Yeh Lin; Kai-Wei Lo; Chia-Hsin Lu; Chang-Lin Hung; Chi-Yuan Chen; Chien-Chung Chang; Yu-Chen Hu
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

2.  Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Authors:  Alaina J Mooney; S Mark Tompkins
Journal:  Future Virol       Date:  2013-01-01       Impact factor: 1.831

Review 3.  Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines.

Authors:  Marine L B Hillaire; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  J Biomed Biotechnol       Date:  2011-10-05

4.  Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine.

Authors:  Hansam Cho; Hee-Jung Lee; Yoon-Ki Heo; Yeondong Cho; Yong-Dae Gwon; Mi-Gyeong Kim; Ki Hoon Park; Yu-Kyoung Oh; Young Bong Kim
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

Review 5.  Baculovirus Surface Display of Immunogenic Proteins for Vaccine Development.

Authors:  Balraj Premanand; Poh Zhong Wee; Mookkan Prabakaran
Journal:  Viruses       Date:  2018-05-31       Impact factor: 5.048

Review 6.  Baculovirus as a gene delivery vector: recent understandings of molecular alterations in transduced cells and latest applications.

Authors:  Chi-Yuan Chen; Chin-Yu Lin; Guan-Yu Chen; Yu-Chen Hu
Journal:  Biotechnol Adv       Date:  2011-04-28       Impact factor: 14.227

7.  An Integrated Platform for Serological Detection and Vaccination of COVID-19.

Authors:  Sung-Chan Wei; Wei-Ting Hsu; Chun-Hsiang Chiu; Feng-Yee Chang; Huei-Ru Lo; Chuan-Yu Liao; Hwai-I Yang; Yu-Chi Chou; Chih-Hsuan Tsai; Yu-Chan Chao
Journal:  Front Immunol       Date:  2021-12-23       Impact factor: 7.561

8.  Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs.

Authors:  Hee-Jung Lee; Yoon-Ki Hur; Youn-Dong Cho; Mi-Gyeong Kim; Hoon-Taek Lee; Yu-Kyoung Oh; Young Bong Kim
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

9.  Induction of robust immunity response in mice by dual-expression-system-based recombinant baculovirus expressing the capsid protein of porcine circovirus type 2.

Authors:  Yu Ye; Xiaoliang Cheng; Jie Zhang; Tiezhu Tong; Wenyao Lin; Ming Liao; Huiying Fan
Journal:  Virol J       Date:  2013-10-28       Impact factor: 4.099

10.  Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1.

Authors:  Yong-Dae Gwon; Sehyun Kim; Yeondong Cho; Yoonki Heo; Hansam Cho; Kihoon Park; Hee-Jung Lee; Jiwon Choi; Haryoung Poo; Young Bong Kim
Journal:  PLoS One       Date:  2016-05-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.